FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!
March 24, 2022
Recursion dazzled investors with a tantalizing pitch: We are a biotech scaling more like a tech company.
The potential to boost the scale and efficiency of drug development by automating wet labs and applying machine learning to the resulting data led investors to hand Recursion $502 million to take four drugs into phase 2 and advance six other programs up to the cusp of the clinic.
The company has advanced its internal pipeline while continuing business development activities.
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS